May 8th 2025
A study reveals higher health care costs and resource use for uncomplicated urinary tract infections (uUTIs), emphasizing the need for improved patient management strategies.
National Alliance Guideline Identifies Key PBM Concerns for Health Plan Purchasers
September 7th 2023The playbook includes resources for purchasers to help in their dealings with pharmacy benefit managers (PBMs), including best practice checklists, sample questionnaires for choosing consultants, and recommendations for contracting language.
Read More
Dr G. B. John Mancini on Payer System Differences Between the US and Canada
September 7th 2023Care quality is high in both the United States and Canada, but there are commonalities in regard to drug access and cost issues, particularly with advanced medications, noted G. B. John Mancini, MD, University of British Columbia.
Watch
What We’re Reading: Worker Heat Safety; COVID-19 Anxiety; Nursing Home Staffing Rule
September 5th 2023Rising temperatures demand action against heat-related illnesses; school superintendents face complex decisions as COVID-19 cases rise; national staffing standards for nursing homes present challenges.
Read More
Laura Wingate: Biosimilars Can Improve Access to Treatment for Patients
September 3rd 2023Biosimilars can improve access to treatment for patients who might not have been able to access biologics previously, explained Laura Wingate, executive vice president, Education, Support, & Advocacy, Crohn's & Colitis Foundation.
Watch
Cost Analysis of Self-Monitoring Blood Glucose in Nonintensively Managed Type 2 Diabetes
Analysis of claims data showed reduced utilization and costs among patients with nonintensively managed type 2 diabetes using self-monitoring of blood glucose compared with continuous glucose monitoring.
Read More
Stelara and Enbrel Chosen for IRA Price Negotiation
August 31st 2023The Biden administration has released the first 10 drugs subject to price negotiation with Medicare under the Inflation Reduction Act (IRA), and among those chosen were Stelara (ustekinumab) and Enbrel (etanercept), both of which will face biosimilar competition within the next decade.
Read More
What We’re Reading: Unpaid Medical Debt; COVID-19 and Hypertension; SNAP Work Requirement Changes
August 21st 2023About 17 million middle-class Americans have unpaid medical bills; more than 1 in 5 patients hospitalized with COVID-19 developed high blood pressure; work requirements for Supplemental Nutrition Assistance Program (SNAP) benefits to begin in September.
Read More
Dr Kevin Davies Discusses Challenges of Streamlining CRISPR Technology Delivery
August 19th 2023Kevin Davies, PhD, executive editor, The CRISPR Journal and GEN Biotechnology, and author of Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing, discusses the difficulties inherent in making CRISPR gene editing technology an equitable treatment.
Watch
Quality vs Convenience: Rural Cancer Patients Weigh Options for Surgical Care
August 17th 2023“Our study suggests that narrowly focusing on hospital volumes and tying that to insurance reimbursement might mask complexities and trade-offs in achieving the goal of optimizing patient outcomes and experiences,” lead co-author Lindsay Sabik, PhD, says.
Read More
Cost Burden of Hospital-Onset CDI Higher Than Community-Associated CDI
August 11th 2023Researchers found that costs were highest for those with hospital-onset clostridioides difficile infection (CDI), lower for those with community onset-health care facility association CDI, and lowest for those with community-associated CDI.
Read More